Delayed elimination of enoxaparine in patients with chronic renal insufficiency
- 1 August 1991
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 63 (3), 385-390
- https://doi.org/10.1016/0049-3848(91)90141-i
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Unfractionated Heparin and CY 216: Pharmacokinetics and Bioavailabilities of the Antifactor Xa and IIa Effects after lntravenous and Subcutaneous Injection in the RabbitThrombosis and Haemostasis, 1989
- The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mgThe Journal of Clinical Pharmacology, 1988
- Pharmacokinetics of Heparin and Low Molecular Weight Heparin Fragment (Fragmin®) in Rabbits with Impaired Renal or Metabolic ClearanceThrombosis and Haemostasis, 1987
- Low molecular weight heparin half life is prolonged in haemodialysed patientsThrombosis Research, 1986
- Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbitsThrombosis Research, 1985
- Heparin Pharmacokinetics: Increased Requirements in Pulmonary EmbolismBritish Journal of Haematology, 1978
- RAPID EVALUATION OF CREATININE CLEARANCEActa Medica Scandinavica, 1974